Project Grant R01CA297605
Award Date
12/3/24
Completion Date
11/30/29
Dollars Obligated
$697K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
New York, NY 10016, USA
Similar Awards
This $703,410 Project Grant, awarded by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), supports research at New York University (NYU) School of Medicine to investigate molecular mechanisms underlying the transition from lung adenocarcinoma to squamous cell carcinoma, which can contribute to resistance to KRAS inhibitor therapies. The research aims to identify chromatin regulators that drive this lineage transition, and systematically decouple the...
The National Cancer Institute (NCI) awarded a $512,974 Project Grant under the Cancer Research Manpower (CFDA 93.398) federal grant program to the Sloan-Kettering Institute for Cancer Research, a non-profit cancer research institution located in New York City. The grant, effective August 13, 2024 through July 31, 2029, will fund research to develop advanced predictive models for non-small cell lung cancer (NSCLC) outcomes using a combination of real-world data sources, including tumor genomic...
The National Cancer Institute (NCI) awarded a $730,400 Project Grant under the Cancer Biology Research program (CFDA 93.396) to the Sloan-Kettering Institute for Cancer Research in New York. The goal of this 5-year project is to determine how specific metabolic configurations in lung adenocarcinoma (LUAD) cancer cells support the emergence and maintenance of treatment-resistant cell states. The research team will manipulate components of the tricarboxylic acid (TCA) cycle in mouse and...
This $3,787,956.00 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research by New York University School of Medicine to investigate and target replication stress in small cell lung cancer (SCLC). The research aims to: 1) understand how the SLFN11 gene impacts chemotherapy response in SCLC subtypes, 2) study how replication stress response pathways and modulators regulate chemosensitivity, and 3) develop strategies to target replication...
The National Cancer Institute (NCI), under the Federal Grant Program "Cancer Research Manpower" (CFDA 93.398), awarded a $128,228 Project Grant to The Trustees of Columbia University in the City of New York. The grant, titled "Inhalable Extracellular Vesicles Engineering for Lung Cancer Treatment," aims to pioneer precision therapeutics for lung cancer by enhancing IL-12-induced immunotherapy and elucidating the mechanisms by which cardiac fibrosis may exacerbate lung cancer....
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $158,365 to the University of North Carolina at Chapel Hill to study the effects of NRF2 signaling on the development of lung squamous cell carcinoma (LUSC). The research aims to understand how NRF2 activation impacts LUSC initiation, progression, and the tumor microenvironment using a novel genetically-engineered mouse model. The University of Washington will perform multi-omics...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $355,706 to The Washington University, located in Missouri, to conduct research focused on understanding the role of the long non-coding RNA RAMS11 in promoting non-small cell lung cancer (NSCLC). The research aims to determine how RAMS11 regulates the transcriptional activity of the NRF2 signaling pathway and drives oncogenic phenotypes in NSCLC, particularly in patients with...
The National Cancer Institute (NCI) awarded a $602,881 Project Grant under CFDA 93.395, the Cancer Treatment Research program, to Duke University. The grant supports research to develop novel immunotherapies using engineered IgG antibodies that can penetrate tumor cells and neutralize oncogenic mutations, such as KRAS. The research aims to translate these tumor cell-penetrating antibodies into the clinic, overcoming challenges associated with the low yield and half-life of previous recombinant...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $649,679 to support research by The Institute For Cancer Research aimed at triggering a viral mimicry response in small cell lung cancer (SCLC) to enhance immunotherapy responsiveness. The key objectives are to determine how targeting the DHX9 helicase protein can induce the accumulation of immunogenic double-stranded RNAs and RNA-DNA hybrids in SCLC cells, leading to antiviral...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $557,418 to The Trustees of Columbia University in the City of New York to conduct research on targeting SMARCA2 in SMARCA4-deficient lung cancers. The research aims to assess the effects of SMARCA2 degradation on SMARCA4-deficient lung cancer progression, elucidate the mechanisms underlying the relationship between SMARCA2 and SMARCA4, and develop effective combinatorial approaches...